Stock List

Search by Ticker



Horizon Therapeutics Public Lim (NASDAQ:HZNP)
Stock Analysis

▼ -7.84%-5.99

Stock Analysis

The following stock analysis is based on 8 years of data (i.e. since Jul 23, 2012). All the stock history has been downloaded.

Stock Exchange

Horizon Therapeutics Public Lim trades on the NasdaqGS exchange in USD dollars.


It is in the healthcare sector.

Current Status of Horizon Therapeutics Public Lim

It is currently trading at $70.39 ($76.38 the previous day).


The next reporting date is in 94 days (2020 11 09).

CNN estimates profits for the upcoming quarter will be $0.83 per share ($476.3M). The current Canada / US exchange rate is 1.32805.

Over the past 12 months, $0 worth of shares have been purchased and $48293805 worth of shares have been sold by insiders.

Will This Trend Continue?

The year over year average increase is 16.8% per year assuming steady exponential growth. The actual 5 year average is 14.46. Details on the individual increase in one year intervals is provided below.

Past PerformanceAverage PricePercent Change
1 year33.87758504672948.7+ Above Average
2 year22.78717491289254.3+ Above Average
3 year14.764728033473-4.5- Below Average
4 year15.456897959184-21.1- Below Average
5 year19.579660377358-5.1- Below Average
Horizon Therapeutics Public Lim is projected by analysts to get to $100.00 within the next 12 months (42.1%), but preticted targets range from as high as $123.00 (74.7%) and as low as $42(-40.3%).


The worst drop it has had in recent years is -74.9%. It has a few bumps shape to the stock curve, which means the stock generally continues on a consistent trend and does not have to be checked often, but can have some variation during periods of volitility.

Stock shape test


With an average increase of 16.8% year over year, if Horizon Therapeutics Public Lim is bought at the worst time, Stockmarketizer analysts estimate it will take 53.5 months before the stock will recover to the original purchase price. The P/E value is 23.98. The stock is under valued as the industry standard in the healthcare sector is a P/E of 86.26.

Tradingview BuySell Widget

Yahoo News Feed

Horizon Therapeutics Named 2020 Top Workplace for Millennials by Fortune

Thu, 06 Aug 2020 13:00:00 Horizon Therapeutics plc (NASDAQ: HZNP) today announced that it has been named to the 2020 Fortune Best Workplaces for Millennials™ list. Horizon ranked 7th among 25 companies in the small and medium company category in its first year on the list.... Read Full Article

Horizon Therapeutics plc Announces Proposed Public Offering of Ordinary Shares

Wed, 05 Aug 2020 20:01:00 Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it is offering to sell $700,000,000 of its ordinary shares in an underwritten public offering. The Company also expects to grant the underwriters a 30-day option to purchase up to an additional $105,000,000 of ...... Read Full Article

Why Horizon Therapeutics Stock Is Up Today

Wed, 05 Aug 2020 16:26:00 Shares of Horizon Therapeutics (NASDAQ: HZNP) are up by 17% as of 11:54 a.m. EDT on Wednesday, after the company reported better-than-expected second-quarter financial results before the market opened today. During the second quarter, Horizon Therapeutics' net sales soared by 44% year ...... Read Full Article

Recap: Horizon Therapeutics Q2 Earnings

Wed, 05 Aug 2020 11:46:01 Shares of Horizon Therapeutics (NASDAQ:HZNP) were unchanged after the company reported Q2 results.Quarterly Results Earnings per share fell 18.37% over the past year to $0.40, which beat the estimate of $0.34.Revenue of $462,779,000 up by 44.33% from the same period last year, ...... Read Full Article

Horizon Therapeutics plc Reports Record Second-Quarter 2020 Results; Increases TEPEZZA® Full-Year Net Sales Guidance to Greater Than $650 Million; Increases Full‐Year 2020 Net Sales and Adjusted EBITDA Guidance

Wed, 05 Aug 2020 11:00:00 Horizon Therapeutics Record Second-Quarter 2020 Results; Increased Guidance... Read Full Article

New Topline TEPEZZA® (teprotumumab-trbw) Data Underscore its Efficacy in Longer Disease Duration, Long-Term Durability and Potential for Retreatment in People Living with Thyroid Eye Disease (TED)

Fri, 31 Jul 2020 11:00:00 Horizon announced topline data adding to the growing body of evidence supporting the efficacy and safety of TEPEZZA for Thyroid Eye Disease (TED).... Read Full Article

Horizon Therapeuticsand' (NASDAQ:HZNP) Wonderful 383% Share Price Increase Shows How Capitalism Can Build Wealth

Fri, 24 Jul 2020 18:25:43 We think that itand's fair to say that the possibility of finding fantastic multi-year winners is what motivates many...... Read Full Article

Target Enrollment Reached in MIRROR Randomized Controlled Trial Evaluating KRYSTEXXA® (pegloticase injection) Co-Prescribed with Methotrexate as an Immunomodulator to Enhance Response Rates for People Living with Uncontrolled Gout

Wed, 22 Jul 2020 12:00:00 Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company has reached target patient enrollment for its Methotrexate to Increase Response Rates in Patients With Uncontrolled GOut Receiving KRYSTEXXA [(MIRROR) randomized controlled trial (RCT)]. MIRROR RCT is the largest randomized ...... Read Full Article

Horizon Therapeutics plc to Release Second-Quarter 2020 Financial Results and Host Webcast on Aug. 5, 2020

Mon, 13 Jul 2020 12:30:00 Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its second-quarter 2020 financial results will be released on Wednesday, Aug. 5, 2020. Following the announcement, Horizonand's management will host a live webcast at 8 a.m. Eastern Time to review the Companyand's financial and operating ...... Read Full Article

Centers for Medicare and Medicaid Services (CMS) Issues Permanent J-Code for TEPEZZA® (teprotumumab-trbw) Effective Oct. 1, 2020

Thu, 09 Jul 2020 12:30:00 Horizon Therapeutics announced that the U.S. Centers for Medicare and Medicaid Services has assigned a permanent J-code (J3241) for TEPEZZA.... Read Full Article

HemoShear Therapeutics Achieves Milestone in Exclusive Drug Discovery Collaboration with Horizon Therapeutics in Gout

Thu, 09 Jul 2020 12:00:00 HemoShear Therapeutics, LLC, a privately held clinical stage biotechnology company, has achieved a research milestone in its collaboration with Horizon Therapeutics plc (Nasdaq: HZNP) to discover and develop novel therapeutics for gout. In fewer than 18 months, HemoShearand's team has made ...... Read Full Article

Why These 3 Pharma Stocks Are Outplaying 90% Of The Stock Market

Wed, 08 Jul 2020 14:00:07 Pharmaceutical stocks dipped by a single-digit percentage in the first six months of 2020, trailing their biotech brethren. Still, there are standout companies in the group.... Read Full Article

Were Hedge Funds Right About Horizon Therapeutics Public Limited Company (HZNP) ?

Tue, 07 Jul 2020 20:49:32 The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge ...... Read Full Article

New Initiative Encourages the Graves’ Disease Community to FOCUS on Eye Health

Wed, 01 Jul 2020 13:00:00 Horizon Therapeutics and Prevent Blindness launch an initiative encouraging people with Graves’ disease to FOCUS on their Thyroid Eye Disease (TED).... Read Full Article

These 3 Growth Stocks Could Hold Value

Tue, 23 Jun 2020 15:38:33 Horizon Therapeutics PLC tops the list Continue reading...... Read Full Article

Horizon Therapeutics plc Announces Redemption of All $400 Million of Its Exchangeable Senior Notes

Wed, 03 Jun 2020 12:05:00 Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it issued a notice of redemption for all $400 million of its 2.50% exchangeable senior notes due 2022. The redemption date is August 3, 2020. The exchangeable senior notes may be exchanged by holders at any time ...... Read Full Article

Is Horizon Therapeutics (HZNP) A Good Stock To Buy?

Sat, 30 May 2020 17:06:41 We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the fundsand' and investorsand' portfolio positions as of March 31st, near the height of ...... Read Full Article

Edited Transcript of HZNP earnings conference call or presentation 6-May-20 12:00pm GMT

Wed, 27 May 2020 19:36:46 Q1 2020 Horizon Therapeutics PLC Earnings Call... Read Full Article

Horizon Therapeutics Named Number One Best Workplace in Chicago

Thu, 21 May 2020 13:15:00 Horizon Therapeutics plc (NASDAQ: HZNP) today announced that it has been named No. 1 on the Great Place to Work® and"Best Workplaces in Chicago 2020and" list in the small and medium category. The list includes 39 other top small-to-medium sized companies, ...... Read Full Article

Data on Multiple Immunomodulation Approaches with KRYSTEXXA® (pegloticase injection) to be Presented at the Annual European Congress of Rheumatology (EULAR 2020)

Thu, 21 May 2020 12:00:00 Horizon Therapeutics plc (Nasdaq: HZNP) announced today that multiple case series and studies will be presented at the Annual European Congress of Rheumatology (EULAR 2020), being held virtually June 3 - 6, 2020. Several presentations of clinical trial data and in-practice cases will provide ...... Read Full Article